BRAF and colorectal carcinoma: However, in CRC harboring these mutations, response rates to the BRAF inhibitors vemurafenib or dabrafenib and MEK1/2 inhibition with trametinib were low due to adaptive feedback reactivation of upstream RTKs and RAS.